On September 13, 2009
Why Vivus’s Qnexa Might Avoid the Obesity Drug Graveyard
Vivus’s better-than-expected Phase III data with obesity drug Qnexa started the goldmine versus graveyard debate once again. In one corner: the folks who think obesity is the last frontier. In the other corner: the folks like BNET’s own Jim Edwards, who argues that obesity drugs are doomed to failure.
0 Comments